Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Disc Medicine
Biotech
Disc lays off 20% of workforce in wake of FDA rejection
Disc Medicine is laying off a fifth of its workforce as the biotech reels from the FDA’s rejection of its rare blood disease candidate.
James Waldron
Mar 3, 2026 10:45am
PitchBook expects disciplined biopharma VC recovery in 2026
Feb 16, 2026 12:01am
Disc's rare disease drug hit by FDA rejection
Feb 13, 2026 5:00pm
Regeneron, Sanofi receive 1- to 2-month priority review vouchers
Oct 17, 2025 8:30am
Disc to spin up confirmatory trial after FDA agrees to design
Jan 21, 2025 9:45am
MHRA CEO Raine to depart in Autumn —Chutes & Ladders
Mar 1, 2024 9:30am
